Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 11/20 | 0.71 |
| ▸ | HTR2C | P28335 | 11/20 | 0.71 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23875880 | 1.00 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL23875899 | 1.00 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| Hydrochloric Acid SCHEMBL18669413 | 0.99 | HTR7 (0.76) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL274149 | 0.88 | HTR7 (1.00) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL30274365 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL30274410 | 0.86 | HTR7 (0.83) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL763734 | 0.86 | HTR2C (0.85) | HTR2AHTR2C | |
| SCHEMBL3709723 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL6786360 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL6089057 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146220-A | Method for synthesizing dihydro-beta-carboline by oxidative dehydrogenation of tetrahydro-beta-carboline | 西安石油大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| CN-115850269-A | Tetrahydro-beta-carboline compound and preparation method and application thereof | 南京工业大学 | 2023-03-28 | — | — | CN | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| WO-2009042815-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-6720331-B2 | HAVING ANTI-MITOTIC ACTIVITY FOR THERAPY OF CANCER | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2004-04-13 | — | — | US | disclosed |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2003-02-27 | — | — | US | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | HTR7 3317/4885CYP3A4 860/4885CYP2D6 1833/4885 |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | DCK, CCR1, CCNT1 | HTR7 928/4885CYP3A4 524/4885CYP2D6 110/4885 |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR7 4366/4885CYP3A4 4614/4885CYP2D6 4809/4885 |
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | HTR7 3317/4885CYP3A4 860/4885CYP2D6 1833/4885 |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | HTR7 3547/4885CYP3A4 4476/4885CYP2D6 4379/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | HTR7 3935/4885CYP3A4 3112/4885CYP2D6 4147/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | HTR7 3317/4885CYP3A4 860/4885CYP2D6 1833/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR7 3584/4885CYP3A4 4808/4885CYP2D6 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.